Arrowhead Pharmaceuticals, Inc. ARWR 深 沪
等待开盘 09-23 09:30:00 美东时间
71.86
+3.070
+4.46%
华盛通- 最 高72.365
- 今 开68.85
- 成交量 311.59万股
- 最 低 68.08
- 昨 收 68.79
- 总市值 101.51亿
- 52周最高 95.4899
- 市盈率 静 --
- 换手率 2.21%
- 52周最低 34.61
- 委 比 -95.63%
- 总股本 1.41亿
- 历史最高 95.4899
- 量 比 0.82
- 振 幅 6.23%
- 历史最低 1.22
- 每 手 1
- 风险率 16.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股周涨跌榜 | AI医疗概念周内狂飙！Tempus AI劲升32%，CEO释放长期增长指引；TWST升31%
AI医疗概念周内狂飙！Tempus AI劲升32%，CEO释放长期增长指引；TWST升31%，与礼来TuneLab达成合作；FPS升24%，2027财年业绩指引大超预期>>
09-20 09:30
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperli...
09-16 19:39
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108
Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
09-09 00:04
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
08-31 21:11
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Mu...
08-31 15:47
美股夜盘 | 德希尼布FMC小升2.78%，雪佛龙小升2.48%
德希尼布FMC小升2.78%；雪佛龙小升2.48%；Arrowhead Pharmaceuticals, Inc.小升2.38%
08-31 09:01
